NCT03043391 · OUTCOME

Overall Survival

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children · Source last updated 2024-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: up to 24 months

What was measured

Estimation of overall survival calculated at the time between lerapolturev infusion and death or last follow-up if the participant is alive using the Kaplan-Meier method

Groups in this outcome

All Participants Treated

All participants received a single lerapolturev infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants Treated	8

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Participants Treated	4.1	Not reported	1.2	10.1	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.2
upper Limit
10.1
value
4.1

denoms

counts
group Id
OG000
value
8
units
Participants

description

Estimation of overall survival calculated at the time between lerapolturev infusion and death or last follow-up if the participant is alive using the Kaplan-Meier method

dispersion Type

95% Confidence Interval

groups

description
All participants received a single lerapolturev infusion.
id
OG000
title
All Participants Treated

param Type

MEDIAN

reporting Status

POSTED

time Frame

up to 24 months

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice